The strange reason flu shots have been so hard to improve
By Ray Dombrowski ·
The whole performance around flu shots feels less like public health advice and more like an exercise in regulatory theater.
When a $500 Million Bet Is Audited Against A Spreadsheet
The whole performance around flu shots feels less like public health advice and more like an exercise in regulatory theater. We are supposed to believe that science is progressing linearly, that every little committee meeting or FDA approval moves us closer to some perfect prophylactic shield. But when you audit the process—when you score it against actual payroll numbers—the whole thing looks shaky.
The facts presented this year paint a picture of deep instability. The Department of Health and Human Services canceled 22 mRNA vaccine projects worth roughly $500 million, while Robert F. Kennedy Jr., Health Secretary, claimed data showed vaccines fail to protect against upper respiratory infections like Covid and flu (yahoo.com). Meanwhile, the FDA approved mFLUSIVA, the first mRNA influenza vaccine ever licensed in the United States, on August 5, 2026—a date that landed precisely one year after an initial deadline set by the agency itself. The decision followed a bizarre regulatory dance: the FDA initially refused to review Moderna’s application before reversing course fifteen days later.
This isn't about virology; it's about process failure. We are told, repeatedly, that the traditional flu shot—the one grown in fertilized chicken eggs—is outdated and slow, running a six-month cycle just for incubation alone. While mRNA technology promises speed, allowing a vaccine to go from strain selection to finished product in two or three months, the regulatory environment seems incapable of handling its own success.
The Contradictory Efficacy Rates Are Not Evidence
The real story isn’t who is right about the molecular structure; it’s what happens when you look at efficacy rates and hospitalizations through a non-political lens. When looking at the 2024–25 season, the CDC estimated 45,000 deaths from flu. But then we get reports like Nicolas Hulscher's study published on publichealthpolicyjournal.com, which found that influenza vaccination was associated with a higher risk of influenza for working-aged adults during the same period. The analysis yielded a calculated vaccine effectiveness of −26.9%.
Of course, there are counter-narratives—the AP News reported that this season’s vaccines were around 25% to 30% effective in preventing hospital visits. But these numbers do not negate the underlying systemic problem: the inability of the current system to reliably measure and communicate risk without political interference. The sheer volatility of the data, swinging from massive estimated death tolls to negative calculated effectiveness rates, reveals a profound lack of stable institutional process.
Policy Whims Are Not Infrastructure Planning
The pattern repeats itself across decades. When novel medical countermeasures are needed against rapidly evolving pathogens—like the global pandemic of HIV/AIDS, which began in 1981—the development and deployment are frequently hampered by systemic failures in funding, regulatory processes, and the politicization of scientific consensus. The shared mechanism is undeniable: progress stalls when policy input becomes subject to political whim rather than consistent, evidence-based auditing.
What we are watching unfold in the flu shot debate is not scientific disagreement; it’s institutional drift. It is exactly the same failure that plagued the HIV/AIDS epidemic response decades ago—a breakdown of stable funding and regulatory commitment due to shifting political priorities. The focus shifts from "how many people are getting hired" (the payroll) to "what sounds good in a press release."
The American economy runs on reliable infrastructure, whether that's the rail lines or the vaccine supply chain. When the regulatory process—which is meant to be the load-bearing institution of public health—is treated as a political commodity, it fails. The system cannot afford this level of instability; it simply lacks the foundational consistency required for complex, long-term medical development.